Evidence map›Paper›PMID 42393634›Full record

ArticleBMC public health2026

Implementation, coverage and impact of a programmatic mass drug administration campaign for malaria in southern Mozambique.

Maria Tusell, Laura Fuente-Soro, Arsénio Nhacolo, Helena Martí-Soler, Jacopo Vecchio, Amancio Nhangave, Khalid Bapu, Felimone Amone, Christina Riley, Orcídio Chivite and 12 more

Abstract read
In one paragraph

Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Maria TusellBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain. maria.tusell@isglobal.org.
Laura Fuente-SoroBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Arsénio Nhacolo *Manhiça Health Research Centre, Maputo, Mozambique.
Helena Martí-Soler *Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Jacopo VecchioBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
Amancio NhangaveGaza Provincial Directorate of Health, Xai-Xai, Mozambique.
Khalid BapuManhiça Health Research Centre, Maputo, Mozambique.
Felimone AmoneManhiça Health Research Centre, Maputo, Mozambique.
Christina RileyAkros Research, Lusaka, Zambia.
Orcídio ChiviteManjacaze District Directorate of Health, Manjacaze, Mozambique.
Nteruma CatorzeZavala District Directorate of Health, Zavala, Mozambique.
Valencia NoveleZavala District Directorate of Health, Zavala, Mozambique.
Wilson SimoneManhiça Health Research Centre, Maputo, Mozambique.
Ismail ChiposseGaza Provincial Directorate of Health, Xai-Xai, Mozambique.
Alfa MoianeGaza Provincial Directorate of Health, Xai-Xai, Mozambique.
Alberto GomoManjacaze District Directorate of Health, Manjacaze, Mozambique.
Odety ChissicoManjacaze District Directorate of Health, Manjacaze, Mozambique.
Mércia DimeneNational Malaria Control Program, Ministry of Health, Maputo, Mozambique.
Samira SibindyNational Malaria Control Program, Ministry of Health, Maputo, Mozambique.
Baltazar CandrinhoNational Malaria Control Program, Ministry of Health, Maputo, Mozambique.
Pedro AideManhiça Health Research Centre, Maputo, Mozambique.
Caterina GuinovartBarcelona Institute for Global Health (ISGlobal), Barcelona, Spain.

Funding

European and Developing Countries Clinical Trials Partnership (EDCTP) 2 programme CSA2018HS-2522-ADAM
6 · The paper itself

Abstract

backgroundBetween 2022 and 2023, the Mozambican National Malaria Control Programme developed a locally-tailored implementation strategy for programmatic mass drug administration (pMDA), which was piloted in Chidenguele (Manjacaze District), southern Mozambique. Two rounds of door-to-door pMDA with dihydroartemisinin-piperaquine were conducted, targeting 59,271 individuals in 14,818 households, according to administrative data. Satellite imagery was used to support household enumeration and field navigation.

methodsAn evaluation of the pMDA was conducted. Coverage was assessed using programmatic data and a community household survey (n = 770 individuals). A quasi-experimental design, using neighboring areas not receiving pMDA as a comparison group, was used to evaluate the impact of the pMDA on clinical malaria incidence during the ensuing 22 months through a controlled interrupted time-series analysis of routine surveillance data, adjusting for covariates.

resultsAccording to programmatic data, household availability coverage (households reached/target households) increased from 59.4% (8,796/14,818) in the first round to 94.3% (13,972/14,818) in the second, following optimization of the implementation strategy. Programmatic or contact coverage (individuals treated/target population) increased from 41.2% (24,437/59,271) to 69.7% (41,320/59,271). In the second round, 8% of the target population was not reached, 8.7% were absent during visits, 6.9% were ineligible, and 6.7% refused participation. The household survey showed similar coverages and estimated that 81.6% of respondents (628/770, 95% CI 78.6-84.2) were treated in at least one of the rounds. We found weak evidence of a larger decrease in malaria incidence immediately following the pMDA implementation in the pMDA group versus the comparison group (level change incidence risk ratio [IRR] = 0.66, p = 0.074), and no evidence of a difference in the malaria trend over time between the two groups (trend change IRR = 0.96, p = 0.104).

conclusionsAlthough more than 90% of target households and individuals were reached in the second round, achieving the recommended 80% programmatic coverage remained challenging. This target was reached only when considering participation in either of the two rounds, highlighting the importance of conducting multiple rounds. High coverage requires strong community engagement, household revisits and/or fixed points, and substantial human and logistical resources. Using satellite imagery and triangulating with census data allowed us to estimate denominators, though challenges remain in this process. We found weak evidence of an impact on malaria incidence immediately following the pMDA and no evidence of a difference in the incidence trend over time. Overall, pMDA can be implemented under programmatic conditions, but is resource-intensive and should be reserved for specific contexts alongside other core malaria interventions.

Indexed as

AntimalarialsArtemisininsMalariaMass Drug AdministrationQuinolinesAdolescentAdultChildChild, PreschoolFemaleHumansIncidenceInfantInterrupted Time Series AnalysisMaleMozambiqueAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolinesControlled-interrupted time seriesCoverageImpact evaluationImplementation scienceMalaria eliminationMass drug administrationMixed-methodsMozambique

Identifiers

PMID42393634
PMCPMC13647609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.